Anti-tumor  ||| S:0 E:11 ||| JJ
necrosis  ||| S:11 E:20 ||| JJ
factor  ||| S:20 E:27 ||| NN
therapies  ||| S:27 E:37 ||| NNS
in  ||| S:37 E:40 ||| IN
immune-mediated  ||| S:40 E:56 ||| JJ
rheumatic  ||| S:56 E:66 ||| JJ
diseases ||| S:66 E:74 ||| NNS
.  ||| S:74 E:76 ||| .
Other  ||| S:76 E:82 ||| JJ
observations  ||| S:82 E:95 ||| NNS
from  ||| S:95 E:100 ||| IN
the  ||| S:100 E:104 ||| DT
clinic  ||| S:104 E:111 ||| NN
To  ||| S:111 E:114 ||| TO
date ||| S:114 E:118 ||| NN
,  ||| S:118 E:120 ||| ,
over  ||| S:120 E:125 ||| IN
2  ||| S:125 E:127 ||| CD
million  ||| S:127 E:135 ||| CD
patients  ||| S:135 E:144 ||| NNS
worldwide  ||| S:144 E:154 ||| NNS
have  ||| S:154 E:159 ||| VBP
been  ||| S:159 E:164 ||| VBN
treated  ||| S:164 E:172 ||| VBN
with  ||| S:172 E:177 ||| IN
anti-tumor  ||| S:177 E:188 ||| JJ
necrosis  ||| S:188 E:197 ||| JJ
factor  ||| S:197 E:204 ||| NN
( ||| S:204 E:205 ||| -LRB-
TNF ||| S:205 E:208 ||| NNP
)  ||| S:208 E:210 ||| -RRB-
therapies ||| S:210 E:219 ||| NNS
,  ||| S:219 E:221 ||| ,
dramatically  ||| S:221 E:234 ||| RB
improving  ||| S:234 E:244 ||| VBG
the  ||| S:244 E:248 ||| DT
treatment  ||| S:248 E:258 ||| NN
outcomes  ||| S:258 E:267 ||| NNS
of  ||| S:267 E:270 ||| IN
immune-mediated  ||| S:270 E:286 ||| JJ
inflammatory  ||| S:286 E:299 ||| JJ
diseases  ||| S:299 E:308 ||| NNS
( ||| S:308 E:309 ||| -LRB-
IMID ||| S:309 E:313 ||| NNP
) ||| S:313 E:314 ||| -RRB-
.  ||| S:314 E:316 ||| .
Observations  ||| S:316 E:329 ||| NNS
from  ||| S:329 E:334 ||| IN
clinicians  ||| S:334 E:345 ||| NNS
have  ||| S:345 E:350 ||| VBP
identified  ||| S:350 E:361 ||| VBN
some  ||| S:361 E:366 ||| DT
curious  ||| S:366 E:374 ||| JJ
disconnects  ||| S:374 E:386 ||| NN
between  ||| S:386 E:394 ||| IN
clinical  ||| S:394 E:403 ||| JJ
and  ||| S:403 E:407 ||| CC
radiographic  ||| S:407 E:420 ||| JJ
outcomes ||| S:420 E:428 ||| NNS
,  ||| S:428 E:430 ||| ,
and  ||| S:430 E:434 ||| CC
the  ||| S:434 E:438 ||| DT
paradoxical  ||| S:438 E:450 ||| JJ
occurrence  ||| S:450 E:461 ||| NN
of  ||| S:461 E:464 ||| IN
anti-TNF  ||| S:464 E:473 ||| NNP
therapy-induced  ||| S:473 E:489 ||| NNP
IMID  ||| S:489 E:494 ||| NNP
such  ||| S:494 E:499 ||| JJ
as  ||| S:499 E:502 ||| IN
psoriasis  ||| S:502 E:512 ||| NN
or  ||| S:512 E:515 ||| CC
reactivation  ||| S:515 E:528 ||| NN
of  ||| S:528 E:531 ||| IN
uveitis  ||| S:531 E:539 ||| NN
and  ||| S:539 E:543 ||| CC
Crohn ||| S:543 E:548 ||| NNP
's  ||| S:548 E:551 ||| POS
disease ||| S:551 E:558 ||| NN
.  ||| S:558 E:560 ||| .
These  ||| S:560 E:566 ||| DT
observations  ||| S:566 E:579 ||| JJ
point  ||| S:579 E:585 ||| NN
to  ||| S:585 E:588 ||| TO
the  ||| S:588 E:592 ||| DT
need  ||| S:592 E:597 ||| NN
for  ||| S:597 E:601 ||| IN
a  ||| S:601 E:603 ||| DT
better  ||| S:603 E:610 ||| JJR
understanding  ||| S:610 E:624 ||| NN
of  ||| S:624 E:627 ||| IN
the  ||| S:627 E:631 ||| DT
mechanisms  ||| S:631 E:642 ||| NNS
underlying  ||| S:642 E:653 ||| VBG
the  ||| S:653 E:657 ||| DT
ability  ||| S:657 E:665 ||| NN
of  ||| S:665 E:668 ||| IN
anti-TNF  ||| S:668 E:677 ||| JJ
therapies  ||| S:677 E:687 ||| NNS
to  ||| S:687 E:690 ||| TO
reduce  ||| S:690 E:697 ||| VB
inflammation  ||| S:697 E:710 ||| NNS
and  ||| S:710 E:714 ||| CC
how  ||| S:714 E:718 ||| WRB
this  ||| S:718 E:723 ||| DT
is  ||| S:723 E:726 ||| VBZ
linked  ||| S:726 E:733 ||| VBN
to  ||| S:733 E:736 ||| TO
the  ||| S:736 E:740 ||| DT
pathogenesis  ||| S:740 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
IMID ||| S:756 E:760 ||| NNP
.  ||| S:760 E:762 ||| .
